CN Patent

CN111840218A — 依达拉奉剂型

Assigned to Shanghai Aozong Biotechnology Co ltd · Expires 2020-10-30 · 6y expired

What this patent protects

本发明属于制药领域，具体公开了新型依达拉奉剂型，以及利用依达拉奉治疗人类氧化性应激相关疾病的方法。该方法包括向人类给药治疗有效量的依达拉奉或其可药用盐，通过提升生物利用度、减少其副作用和治疗费用，从而实现最好的治疗输出。

USPTO Abstract

本发明属于制药领域，具体公开了新型依达拉奉剂型，以及利用依达拉奉治疗人类氧化性应激相关疾病的方法。该方法包括向人类给药治疗有效量的依达拉奉或其可药用盐，通过提升生物利用度、减少其副作用和治疗费用，从而实现最好的治疗输出。

Drugs covered by this patent

Patent Metadata

Patent number
CN111840218A
Jurisdiction
CN
Classification
—
Expires
2020-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Aozong Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.